<code id='23E4F1D694'></code><style id='23E4F1D694'></style>
    • <acronym id='23E4F1D694'></acronym>
      <center id='23E4F1D694'><center id='23E4F1D694'><tfoot id='23E4F1D694'></tfoot></center><abbr id='23E4F1D694'><dir id='23E4F1D694'><tfoot id='23E4F1D694'></tfoot><noframes id='23E4F1D694'>

    • <optgroup id='23E4F1D694'><strike id='23E4F1D694'><sup id='23E4F1D694'></sup></strike><code id='23E4F1D694'></code></optgroup>
        1. <b id='23E4F1D694'><label id='23E4F1D694'><select id='23E4F1D694'><dt id='23E4F1D694'><span id='23E4F1D694'></span></dt></select></label></b><u id='23E4F1D694'></u>
          <i id='23E4F1D694'><strike id='23E4F1D694'><tt id='23E4F1D694'><pre id='23E4F1D694'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:2
          Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT
          Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

          After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

          The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

          advertisement

          Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          RSV shot was 90% effective at preventing hospitalizations in kids
          RSV shot was 90% effective at preventing hospitalizations in kids

          Thiselectronmicroscopeimageshowshumanrespiratorysyncytialvirus(RSV)virions,colorizedblue,andanti-RSV

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          The problem with charging patients to message their doctors

          AdobeThinkingaboutmessagingyourphysicianaboutaweirdrash?Youmaywanttoholdoffonit.Somehospitalsystemsh